Sinomenine Ameliorates Liver Fibrosis by Blocking TGF ‐β/ SMAD and c‐ JUN Signaling
Phytotherapy Research · 2025-07 · 39 (7) · 3182-3196
DOI: 10.1002/ptr.8502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, 2025-06. Verfasst von Yichao Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China. Hauptthemen laut MEDLINE: Morphinans, Liver Cirrhosis, Signal Transduction, Transforming Growth Factor beta. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Luzhou Science and Technology Program, National Natural Science Foundation of China, Luzhou Municipal People's Government-Southwest Medical University Science and Technology Strategic Cooperation Project.
Abstract (Originalsprache)
Liver fibrosis, a pivotal pathological feature in the progression of chronic liver injury, currently lacks effective therapies. Sinomenine (SIN), a bioactive alkaloid derived from traditional Chinese medicine, demonstrates diverse pharmacological properties. However, its therapeutic potential and mechanisms in liver fibrosis remain inadequately characterized. This study investigates the anti‐fibrotic effects of SIN and its underlying molecular mechanisms. The anti‐fibrotic efficacy of SIN was evaluated in two murine models of liver fibrosis induced by carbon tetrachloride (CCl 4 ) or bile duct ligation (BDL), along with transforming growth factor‐beta 1 (TGF‐β1)‐stimulated rat hepatic stellate cells (HSC‐T6). Serum biochemical markers, histopathological analyses (Hematoxylin–Eosin, Sirius red, and Masson's trichrome staining), immunofluorescence, and immunohistochemistry were employed to assess hepatic injury and collagen deposition. Western blotting elucidated molecular mechanisms. SIN administration significantly attenuated hepatic injury in CCl 4 ‐ or BDL‐induced mice, as evidenced by reduced transaminase levels and improved histopathological features. In both in vivo and in vitro models, SIN suppressed fibrogenesis by decreasing collagen deposition and downregulating expression of α‐smooth muscle actin (α‐SMA), matrix metalloproteinase 2 (MMP2), and collagen I. Mechanistically, SIN inhibited the TGF‐β/SMAD pathway through reduced phosphorylation of SMAD2/3 and attenuated c‐JUN signaling via diminished phosphorylated c‐JUN levels. Pretreatment with TP0427736 (a SMAD2/3 inhibitor) or SP600125 (a c‐JUN inhibitor) synergistically enhanced SIN‐mediated α‐SMA suppression in HSC‐T6 cells. SIN ameliorates liver fibrosis through inhibition of TGF‐β/SMAD and c‐JUN signaling pathways. These findings position SIN as a promising therapeutic candidate for liver fibrotic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
- Academician (Expert) Workstation of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
- Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
- Clinical Medical Research Center, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
- Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
ORCID-Profile: Yichao Du, Tingting Ma
Förderung
- Luzhou Science and Technology Program
- National Natural Science Foundation of China
- Luzhou Municipal People's Government-Southwest Medical University Science and Technology Strategic Cooperation Project
- the Key Research and Development Program of Shaanxi
- the Scientific Research Foundation of Southwest Medical University of China
- Sichuan Science and Technology Program
- Key Research and Development Projects of Shaanxi Province
Zitieren
APA
Du, Y., Bai, J., Ma, T., Wu, Z., Wang, P., Zhong, X., Fu, W., & He, S. (2025). Sinomenine Ameliorates Liver Fibrosis by Blocking TGF ‐β/ SMAD and c‐ JUN Signaling. Phytotherapy Research, 39(7), 3182-3196. https://doi.org/10.1002/ptr.8502
Vancouver
Du Y, Bai J, Ma T, Wu Z, Wang P, Zhong X, et al. Sinomenine Ameliorates Liver Fibrosis by Blocking TGF ‐β/ SMAD and c‐ JUN Signaling. Phytotherapy Research. 2025;39(7):3182-3196. doi:10.1002/ptr.8502
BibTeX
@article{Du2025,
author = {Du, Yichao and Bai, Junjie and Ma, Tingting and Wu, Ziming and Wang, Pengru and Zhong, Xiaolin and Fu, Wenguang and He, Shuixiang},
title = {Sinomenine Ameliorates Liver Fibrosis by Blocking TGF ‐β/ SMAD and c‐ JUN Signaling},
journal = {Phytotherapy Research},
year = {2025},
volume = {39},
number = {7},
pages = {3182--3196},
doi = {10.1002/ptr.8502}
}
EUVIMED